Please login to the form below

Not currently logged in

Sandoz launches generic oncology treatment in Europe

Lenalidomide can be used to treat patients with haemato-onocology conditions, following recommendations from recent European Society for Medical Oncology (ESMO) guidelines


Sandoz has announced the launch of lenalidomide, a generic oncology treatment that will be available in 19 countries across Europe. The treatment is used for patients with various haemato-onocology conditions, following recommendations from the latest European Society for Medical Oncology (ESMO) guidelines.

Rebecca Guntern, head of Sandoz Europe, said: “We are proud to make life-enhancing cancer treatments more accessible by launching our affordable and effective Sandoz Lenalidomide”.

She added that, as part of the company’s commitment to increasing patient access to essential treatments, the news further adds to its “broad portfolio of more than 50 oncology products, ranging from biologics to chemotherapeutics, hormones and supportive care treatments, covering a wide range of cancer indications".

As the cost of providing treatment to multiple myeloma patients continues to rise, affordability and access to new multiple myeloma treatments presents a significant challenge worldwide. The cost savings from Lenalidomide Sandoz will help to expand access to treatment options for multiple myeloma patients.

Lenalidomide Sandoz will benefit patients with follicular lymphoma, adult patients with transfusion-dependent anaemia and patients with relapsed or refractory mantle cell lymphoma.

Sandoz, a division of Novartis, is a global company working to address unmet medical needs and provide patients with access to generic pharmaceuticals and biosimilars.

It is a leading provider of generic oncology medicine in Europe, with a portfolio that cover 75% of molecules on the WHO’s global Oncology Essential Medicines List.

Article by
Fleur Jeffries

18th February 2022

From: Regulatory



Subscribe to our email news alerts

Featured jobs


Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Virtual MSL/Sales training programs and events
Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
Omnichannel strategies to revolutionize the healthcare professional experience
Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...